A brief discussion on therapeutic options one may consider after progression on lenvatinib therapy for iodine-refractory DTC. Lori Wirth, MD: I do want to shift gears, once again, just to touch ...

Idecabtagene vicleucel (ide-cel) was able to triple progression-free survival and reduce the risk of disease progression or death in a phase 3 trial. Idecabtagene vicleucel (ide-cel; Abecma) from ...

Of these progression-free patients, 12 from a single center with serial MRD assessments were all MRD-negative and imaging-negative at year 5 or later after cilta-cel without additional therapy, ...

Approximately one-third of patients with relapsed or refractory mantle cell lymphoma (MCL) in this study treated with CAR T-cell therapy experienced disease progression, with a median progression time ...